Early vasoactive drugs improve heart failure outcomes

Congestive Heart Failure

Volumn 15, Issue 6, 2009, Pages 256-264

  Peacock, William Frank ^a   Emerman, Charles ^a   Costanzo, Maria R ^b   Diercks, Deborah B ^c   Lopatin, Margarita ^d   Fonarow, Gregg C ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Midwest Heart Specialists   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SCIOS INC   (United States)

^e UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; TROPONIN I; TROPONIN T; VASOACTIVE AGENT;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY;

AGED; CARDIOTONIC AGENTS; CONFIDENCE INTERVALS; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; MALE; ODDS RATIO; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 70649098986     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00112.x     Document Type: Article

References (21)

1. Thom T, Haase N, Rosamond W. Heart Disease and Stroke Statistics - 2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.
2. Gheorghiade M, Zannad F, Sopko G. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
3. Adams KF, Fonarow GC, Emerman CL. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
4. Gheorghiade M, De LL, Fonarow GC. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005, 96:11G-17G.
5. Adamson PB, Magalski A, Braunschweig F. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003, 41:565-571.
6. Cleland JG, Coletta AP, Freemantle N. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005, 7:931-936.
7. Fonarow GC. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE Registry. Heart Fail Rev 2004, 9:179-185.
8. Fonarow GC, Adams KF, Abraham WT. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580.
9. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med 2005, 165:1469-1477.
10. Cleveland W. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979, 74:829-836.
11. Abraham WT, Adams KF, Fonarow GC. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57-64.
12. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540.
13. Gheorghiade M, Gattis WA, O'Connor CM. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
14. Mebazaa A. The SURVIVE-W Trial: Comparison of Dobutamine and Levosimendan on Survival in Acute Decompensated Heart Failure 2005, [abstract]. American Heart Association Scientific Sessions, Presented November 16, 2005
15. Packer M. REVIVE II: Multicenter Placebo-Controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure 2005, [abstract]. American Heart Association Scientific Sessions, Presented November 14, 2005
16. Teerlink JR, McMurray JJ, Bourge RC. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005, 150:46-53.
17. Cuffe MS, Califf RM, Adams KF. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
18. DiDomenico RJ, Park HY, Southworth MR. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 2004, 38:649-660.
19. Johnson W, Omland T, Hall C. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002, 39:1623-1629.
20. Butler J, Forman DE, Abraham WT. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331-338.
21. Hasselblad V, Stough WG, Shah MR. Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial. J Card Fail 2005, 11:S157. [abstract]